VSTM

Verastem, Inc.

5.24

USD

VSTM Earnings Reports

Positive Surprise Ratio

VSTM beat 21 of 41 last estimates.

51%

Next Report

Date of Next Report

May 11, 2026

Estimate for Q1 26 (Revenue/ EPS)

$21.95M

-$0.46

Implied change from Q4 25 (Revenue/ EPS)

+25.18%

-8.00%

Implied change from Q1 25 (Revenue/ EPS)

-41.77%

Verastem, Inc. earnings per share and revenue

On Feb 04, 2026, VSTM reported earnings of -0.50 USD per share (EPS) for Q4 25, beating the estimate of -0.55 USD, resulting in a 9.78% surprise. Revenue reached 17.54 million, compared to an expected 16.88 million, with a 3.86% difference. The market reacted with a -7.51% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.46 USD, with revenue projected to reach 21.95 million USD, implying an decrease of -8.00% EPS, and increase of 25.18% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Verastem, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Verastem, Inc. reported EPS of -$0.50, beating estimates by 9.78%, and revenue of $17.54M, 3.86% above expectations.

How did the market react to Verastem, Inc.'s Q4 2025 earnings?

The stock price moved down -7.51%, changed from $6.79 before the earnings release to $6.28 the day after.

When is Verastem, Inc. expected to report next?

The next earning report is scheduled for May 11, 2026.

What are the forecasts for Verastem, Inc.'s next earnings report?

Based on 6 analysts, Verastem, Inc. is expected to report EPS of -$0.46 and revenue of $21.95M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.